Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jan;21(1):58–61. doi: 10.1128/aac.21.1.58

Effect of probenecid on the pharmacokinetics of moxalactam.

K A DeSante, K S Israel, G L Brier, J D Wolny, B L Hatcher
PMCID: PMC181829  PMID: 6211135

Abstract

The effects of probenecid on the pharmacokinetics of moxalactam were studied in normal volunteers administered a 2-min l-g intravenous infusion. The results showed that probenecid did not alter the plasma or urinary concentrations of moxalactam, its apparent volume of distribution, plasma elimination half-life, elimination rate constant, or plasma and renal clearances. Therefore, moxalactam appears to be eliminated primarily by the kidney via glomerular filtration.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bint A. J., Reeves D. S., Holt H. A. Effect of probenecid on serum cefoxitin concentrations. J Antimicrob Chemother. 1977 Nov;3(6):627–628. doi: 10.1093/jac/3.6.627-a. [DOI] [PubMed] [Google Scholar]
  2. Bolton W. K., Scheld W. M., Spyker D. A., Overby T. L., Sande M. A. Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1980 Dec;18(6):933–938. doi: 10.1128/aac.18.6.933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Estey E. H., Weaver S. S., Ho D. H., Bodey G. P. Clinical pharmacology of moxalactam in patients with malignant disease. Antimicrob Agents Chemother. 1981 Apr;19(4):639–644. doi: 10.1128/aac.19.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Foley T. H., Jones N. F., Barraclough M. A., Cranston W. I., Hunt A. P. The renal excretion of cephaloridine in man. Postgrad Med J. 1967 Aug;43(Suppl):85–87. [PubMed] [Google Scholar]
  5. Gibaldi M., Davidson D., Plaut M. E., Schwartz M. A. Modification of penicillin distribution and elimination by probenecid. Int Z Klin Pharmakol Ther Toxikol. 1970 May;3(2):182–189. [PubMed] [Google Scholar]
  6. Gibaldi M., Schwartz M. A. Apparent effect of probenecid on the distribution of penicillins in man. Clin Pharmacol Ther. 1968 May-Jun;9(3):345–349. doi: 10.1002/cpt196893345. [DOI] [PubMed] [Google Scholar]
  7. Griffith R. S., Black H. R., Brier G. L., Wolny J. D. Effect of probenecid on the blood levels and urinary excretion of cefamandole. Antimicrob Agents Chemother. 1977 May;11(5):809–812. doi: 10.1128/aac.11.5.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kislak J. W., Steinhauer B. W., Finland M. Cephaloridine activity in vitro and absorption and urinary excretion in normal young men. Am J Med Sci. 1966 Apr;251(4):433–448. [PubMed] [Google Scholar]
  9. Newburger J., Wagner J. G., Stavchansky S. A method to predict infinity values for biexponential processes. J Pharmacokinet Biopharm. 1979 Aug;7(4):417–425. doi: 10.1007/BF01062539. [DOI] [PubMed] [Google Scholar]
  10. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Scheld W. M., Spyker D. A., Donowitz G. R., Bolton W. K., Sande M. A. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother. 1981 Apr;19(4):613–619. doi: 10.1128/aac.19.4.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sedman A. J., Wagner J. G. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976 Jul;65(7):1006–1010. doi: 10.1002/jps.2600650713. [DOI] [PubMed] [Google Scholar]
  13. Srinivasan S., Fu K. P., Neu H. C. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers. Antimicrob Agents Chemother. 1981 Feb;19(2):302–305. doi: 10.1128/aac.19.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tuano S. B., Brodie J. L., Kirby W. M. Cephaloridine versus cephalothin: relation of the kidney to blood level differences after parenteral administration. Antimicrob Agents Chemother (Bethesda) 1966;6:101–106. [PubMed] [Google Scholar]
  15. Vlasses P. H., Holbrook A. M., Schrogie J. J., Rogers J. D., Ferguson R. K., Abrams W. B. Effect of orally administered probenecid on the pharmacokinetics of cefoxitin. Antimicrob Agents Chemother. 1980 May;17(5):847–855. doi: 10.1128/aac.17.5.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. WEINER I. M., WASHINGTON J. A., 2nd, MUDGE G. H. On the mechanism of action of probenecid on renal tubular secretion. Bull Johns Hopkins Hosp. 1960 Jun;106:333–346. [PubMed] [Google Scholar]
  17. Wagner J. G. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm. 1976 Oct;4(5):443–467. doi: 10.1007/BF01062831. [DOI] [PubMed] [Google Scholar]
  18. Welling P. G., Dean S., Selen A., Kendall M. J., Wise R. Probenecid: an unexplained effect on cephalosporin pharmacology. Br J Clin Pharmacol. 1979 Nov;8(5):491–495. doi: 10.1111/j.1365-2125.1979.tb01032.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Yoshida T., Matsuura S., Mayama M., Kameda Y., Kuwahara S. Moxalactam (6059-S), a novel 1-oxa-beta-lactam with an expanded antibacterial spectrum: laboratory evaluation. Antimicrob Agents Chemother. 1980 Mar;17(3):302–312. doi: 10.1128/aac.17.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zacchei A. G., Weidner L. GLC determination of probenecid in biological fluids. J Pharm Sci. 1973 Dec;62(12):1972–1975. doi: 10.1002/jps.2600621214. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES